GlaxoSmithKline has announced a deal to pay as much as $3 billion to Switzerland's Actelion to license a sleep-disorder drug almorexant in yet another example of a major drug firm turning to a smaller rival to build up pipelines.
Sounds like a lot of tablets will have to be sold!
More
No comments:
Post a Comment